Protective Effect Of Dexmedetomidine On Myocardial Ischemia - Reperfusion Injury In Patients Undergoing Coronary Artery Bypass Grafting

Objective:The protection abilities of Dexmedetomidine against myocardial ischemia reperfusion injury in coronary artery bypass graft (CABG) patients, were investigated by dection the concentration changes of troponin I, troponin T, TNF-a and IL-10.Methods:Eighty patients underwent coronary artery bypass graft was randomly divided into4groups: Dex1,2,3and the control group (Con). The patients in the Dex groups received0.5μg/kg (Dexl),0.75μg/kg (Dex2) and1.0μg/kg (Dex3) of Dexmedetomidine before cardiopulmonary bypass. The ejection fraction was monitored pre-anesthesia, post-CBP,6h and24h postsurgery. Blood samples were obtaied for detection of the concentration changes of troponin I, troponin T, TNF-a and IL-10by ABC-ELISA or ELISA. The derived data was prepared by the SPSS16.0sofrwae for the mathematical statistics.Results:In the control and Dex group, the ejection fraction was reduced and the concentration of troponin I, troponin T, TNF-a and IL-10increased evidently. Compared with the control group, Dexmedetomidine treatment improved the ejection fraction and reduced the concentration of troponin I, troponin T, TNF-a and IL-10significantly.Conclusions:By monitoring the concentration of troponin I, troponin T, TNF-a and IL-10, Dexmedetomidine (0.5-1.0μg/kg) was discovered to pretect the heart against reperfusion injury. In the small dose, the protective effectiveness is even obvious.